IP Library › Granted Patent US 11,471,323
Granted Patent B2
US 11,471,323 · App. 16/701,710 · Granted Oct 18, 2022

Combination treatments

Inventor: Leseo L. Rogers (Raleigh, NC)
Assignee: Scion Neurostim, LLC
A61F7/12A61K31/00A61F2007/0005A61F2007/0075A61F2007/0093A61F2007/0096A61F2007/0261
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,471,323
App. No.
16/701,710
Granted
Oct 18, 2022
Kind
B2
Abstract

A method of treating a subject in need thereof, is carried out by (a) administering said subject a therapeutic intervention (e.g., an active agent) in a treatment effective amount; and concurrently (b) administering said subject caloric vestibular stimulation in a treatment effective amount, said caloric vestibular stimulation administered so as to enhance the efficacy of said active agent. In some embodiments, the caloric vestibular stimulation is administered as an actively controlled time varying waveform.

Claims (10)

1. A method of treating a subject afflicted with Alzheimer's disease and in need of treatment thereof, comprising:

(a) administering said subject an active agent in a treatment effective amount; and concurrently

(b) administering said subject caloric vestibular stimulation in a treatment effective amount, said caloric vestibular stimulation administered so as to enhance the efficacy of said active agent, wherein said caloric vestibular stimulation is administered as an actively controlled time varying waveform and the subject is afflicted with Alzheimer's disease.

2. The method of claim 1 , wherein said active agent is administered orally.

3. The method of claim 1 , wherein said active agent is selected from the group consisting of: donepezil, galantamine, memantine, rivastigmine, tacrine, and equivalent and pharmaceutically active isomer(s) and metabolite(s) and thereof.

4. The method of claim 1 , wherein said caloric vestibular stimulation is administered for a time sufficient to induce nystagmus over a period of at least five minutes.

5. The method of claim 1 , wherein said caloric vestibular stimulation comprises a first thermal waveform delivered to a first ear canal of the subject.

6. The method of claim 5 , wherein said caloric vestibular stimulation comprises a second thermal waveform delivered to a second ear canal of the subject.

7. The method of claim 6 , wherein the first and second thermal waveforms are different.

8. The method of claim 1 , wherein said active agent comprises a medication for treatment of Alzheimer's disease, the symptoms of Alzheimer's disease or a combination thereof.

Assignments (1)
CHANGE OF NAME Recorded Jul 21, 2023
From: SCION NEUROSTIM, LLC
To: SCION NEUROSTIM, INC.
Reel/Frame 064360/0875 →
Continuity (16)
Continuation 15654020 · Jul 19, 2017
Continuation 14847580 · Sep 8, 2015
Continuation 13990912
Continuation In Part 12970347 · Dec 16, 2010
Continuation In Part PCTUS2010060764 · Dec 16, 2010
Continuation In Part 12970312 · Dec 16, 2010
Provisional Application 61498943 · Jun 20, 2011
Provisional Application 61498911 · Jun 20, 2011
Provisional Application 61498080 · Jun 17, 2011
Provisional Application 61498131 · Jun 17, 2011
Provisional Application 61498096 · Jun 17, 2011
Provisional Application 61497761 · Jun 16, 2011
Provisional Application 61424326 · Dec 17, 2010
Provisional Application 61424132 · Dec 17, 2010
Provisional Application 61424474 · Dec 17, 2010
Related Publication 20200214884A1 · Jul 9, 2020